EP Patent

EP1896075A2 — Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor

Assigned to Veloxis Pharmaceuticals AS · Expires 2008-03-12 · 18y expired

What this patent protects

A pharmaceutical composition comprising a CYP3A4 inhibitor and tacrolimus or an analogue thereof, wherein the composition upon administration to a human in need thereof results in a relative AUCinvention/AUC separate value of tacrolimus of at least about 1.1 , the AUC values bein…

USPTO Abstract

A pharmaceutical composition comprising a CYP3A4 inhibitor and tacrolimus or an analogue thereof, wherein the composition upon administration to a human in need thereof results in a relative AUCinvention/AUC separate value of tacrolimus of at least about 1.1 , the AUC values being determined under similar conditions and the AUCseparate value is determined after administration of tacrolimus and CYP3A4 inhibitor in separate dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP1896075A2
Jurisdiction
EP
Classification
—
Expires
2008-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Veloxis Pharmaceuticals AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.